Recommended
Recommended
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

0.6431 -0.0237 (-3.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bioxcel Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough." 
Via Benzinga
Twitter Shares Surge Around 8%, Here's 66 Biggest Movers From Yesterday
Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th. 
Via Benzinga
BioXcel Therapeutics: Q1 Earnings Insights
BioXcel Therapeutics (NASDAQ:BTAI) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Oaktree, Qatar Investment Inject $260M In BioXcel To Fund Commercialization Of Schizophrenia Med
Via Benzinga
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Recap: BioXcel Therapeutics Q2 Earnings
  BioXcel Therapeutics (NASDAQ:BTAI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
Upgrades 
Via Benzinga
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Immix Biopharma, Inc. (NASDAQ: IMMX) rose 42.2% to $2.63 in pre-market trading after declining around 14% on Wednesday. Immix Biopharma, last month, announced positive interim data from an... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Preview: BioXcel Therapeutics's Earnings
BioXcel Therapeutics (NASDAQ:BTAI) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that BioXcel... 
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a... 
Via Benzinga
How To Attend BioXcel Therapeutics Q1 2022 Earnings Conference Call
BioXcel Therapeutics (NASDAQ:BTAI) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
Looking Into Bioxcel Therapeutics Inc's Recent Short Interest
Bioxcel Therapeutics Inc's (NASDAQ:BTAI) short percent of float has risen 10.66% since its last report. The company recently reported that it has 1.87 million shares sold short,... 
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For April 7, 2022: SDPR S&P 500, Houghton Mifflin, Sunshine Biopharma And More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... 
Via Benzinga
4 Top Stock Trades for Thursday: MSFT, TWTR, BTAI, PXD
Microsoft, Twitter, BioXcel Therapeutics and Pioneer Natural Resources were our top stock trades for Thursday. Here's the trade now. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 32.4% to $7.43 during Wednesday's regular session. Sunshine Biopharma's stock is trading at a volume of 46.8... 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares jumped 77.7% to $3.5950. Advent Technologies and Hyundai Motor Company entered into technology assessment, sales... 
Via Benzinga
Why BioXcel Therapeutics Stock Is Surging Today
BioXcel Therapeutics Inc (NASDAQ: BTAI) shares are trading higher Wednesday after the company announced that the U.S. Food and Drug Administration approved IGALMI (... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Healthcare Triangle (NASDAQ:HCTI) stock moved upwards by 17.5% to $1.35 during Wednesday's pre-market session. The company's market cap stands at $47.6... 
Via Benzinga
FDA Approves BioXcel's Igalmi - First Orally Dissolving Sublingual Film For Schizophrenia-Associated Agitation
The  
Via Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... 
Via Benzinga
Recap: BioXcel Therapeutics Q4 Earnings
BioXcel Therapeutics (NASDAQ:BTAI) reported its Q4 earnings results on Thursday, March 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.